Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $27.40.

Several research analysts have recently commented on the company. Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. ValuEngine lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Cowen and Company reissued a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Voyager Therapeutics in a research report on Wednesday, May 10th.

Shares of Voyager Therapeutics (NASDAQ VYGR) traded up 1.39% during trading on Friday, hitting $8.73. The stock had a trading volume of 68,855 shares. Voyager Therapeutics has a 12 month low of $8.10 and a 12 month high of $18.25. The company’s market cap is $234.86 million. The stock has a 50-day moving average price of $9.20 and a 200 day moving average price of $10.62.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by $0.11. The company had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. Equities analysts expect that Voyager Therapeutics will post ($2.82) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/08/12/voyager-therapeutics-inc-vygr-given-consensus-rating-of-hold-by-analysts.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. raised its position in shares of Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares in the last quarter. Hershey Trust Co. raised its position in shares of Voyager Therapeutics by 163.0% in the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Voyager Therapeutics during the second quarter valued at about $143,000. Rhumbline Advisers raised its position in shares of Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after buying an additional 4,144 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in shares of Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock valued at $262,000 after buying an additional 1,847 shares in the last quarter. 41.34% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.